MORGANTOWN, W.V., Sept. 24, 2014 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. (OTCQB:PRGB) ("Protea") announced today that the United States Department of Agriculture (USDA) Agricultural Research Service has purchased Protea's LAESI DP-1000 System for direct molecular analysis. The system will be used by the USDA to identify and screen for mycotoxins in food and feed that can be hazardous to humans and animals.
"The ability to directly detect mycotoxins in plants and foods will enable a more comprehensive understanding of how these toxins function, and offers the potential for improving our ability to rapidly test our foods," stated Steve Turner, Protea's CEO. He added, "LAESI's unique ability to directly and immediately analyze living cells will provide the capacity to identify mycotoxins in a high throughput format."
Mycotoxins are toxic secondary metabolites produced by fungi (commonly known as "molds") that can contaminate common foods. Studies have shown that when humans are exposed to small amounts of certain mycotoxins they can develop a wide range of health problems.
The LAESI DP-1000 allows the direct identification of molecules in living cells and fungal colonies, with analysis completed in seconds to minutes. Thus, molecular changes that occur in molds or fungal colonies over time can be identified and tracked. Protea will provide the LAESI DP-1000 system to the USDA coupled with proprietary software for LAESI Data Analytics (Gubbs, Inc.), a data-bridging software that enables rapid processing of large, complex molecular information data files by downstream statistical programs, to enable USDA researchers to analyze molecular information much faster than traditional methods.
About Protea Biosciences Group, Inc.
Protea (OTCQB:PRGB) is a molecular information company providing innovative bioanalytical solutions to the pharmaceutical, agricultural, and life science industries. Protea has developed a new, fully automated, molecular information technology platform, known as "LAESI" (Laser Ablation Electrospray Ionization), that enables the direct analysis of molecules without the need for sample preparation. Large molecular datasets are generated on native biological samples that can also be visually displayed as 2D and 3D images. Protea maintains its own laboratory facilities where services are provided to its clients, using LAESI and complementary technologies and expertise.
Forward-Looking Statements
This press release may contain certain statements relating to future results, which are forward looking statements. These statements are not historical facts, but instead represent only the company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the company's control. It is possible that the company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the company and its business, including factors that potentially could materially affect the company's financial results, are contained in the company's filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Protea and LAESI are registered trademarks of Protea Biosciences Group, Inc.
Gubbs is a registered trademark of Gubbs, Inc.
Protea Biosciences Group, Inc., 955 Hartman Run Road, Morgantown, WV 26505 USA Phone: 304.292.2226 Fax: 304.292.7101 https://proteabio.com/investors
